{
  "id": "topic2",
  "title": "Topic 2: Cancer Genetics - Hereditary Cancer Syndromes",
  "description": "[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.",
  "difficulty": "Intermediate",
  "tags": [
    "cancer",
    "hereditary",
    "BRCA",
    "lynch",
    "tumor-suppressor"
  ],
  "estimatedTime": 16,
  "importance": 1,
  "sections": [
    {
      "id": "quick-navigation",
      "title": "Quick Navigation",
      "content": "**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Chromosomal Disorders](topic1-chromosomal-disorders.md)** | **[‚û°Ô∏è Next: Organ Systems](topic3-organ-systems-a.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üß¨ Cancer Genetics Fundamentals](#-cancer-genetics-fundamentals)\n- [üéÄ Hereditary Breast & Ovarian Cancer](#-hereditary-breast--ovarian-cancer)\n  - [BRCA1/BRCA2 Syndromes ‚≠ê‚≠ê‚≠ê](#brca1brca2-syndromes-)\n  - [Cowden Syndrome (PTEN) ‚≠ê‚≠ê](#cowden-syndrome-pten-)\n  - [Li-Fraumeni Syndrome ‚≠ê‚≠ê](#li-fraumeni-syndrome-tp53-)\n- [üéóÔ∏è Hereditary Colorectal Cancer](#Ô∏è-hereditary-colorectal-cancer)\n  - [Lynch Syndrome ‚≠ê‚≠ê‚≠ê](#lynch-syndrome-)\n  - [Familial Adenomatous Polyposis ‚≠ê‚≠ê‚≠ê](#familial-adenomatous-polyposis-fap-)\n  - [MUTYH-Associated Polyposis ‚≠ê‚≠ê](#mutyh-associated-polyposis-map-)\n- [üß† Phakomatoses (Neurocutaneous Syndromes)](#-phakomatoses-neurocutaneous-syndromes)\n  - [Neurofibromatosis Type 1 ‚≠ê‚≠ê‚≠ê](#neurofibromatosis-type-1-nf1-)\n  - [Neurofibromatosis Type 2 ‚≠ê‚≠ê](#neurofibromatosis-type-2-nf2-)\n  - [Tuberous Sclerosis Complex ‚≠ê‚≠ê](#tuberous-sclerosis-complex-tsc-)\n- [ü´Ä Additional Cancer Syndromes](#-additional-cancer-syndromes)\n- [üß† Study Tips & Mnemonics](#-study-tips--mnemonics)\n- [üìù High-Yield Facts Summary](#-high-yield-facts-summary)\n- [üéØ Practice Questions](#-practice-questions)\n- [üèÅ Topic 2 Completion Checklist](#-topic-2-completion-checklist)\n\n### üîç Quick Syndrome Lookup\n| Syndrome | Gene(s) | Primary Cancers | Key Features | Inheritance |\n|----------|---------|-----------------|--------------|-------------|\n| **BRCA1/2** | BRCA1, BRCA2 | Breast, ovarian | Early onset, family history | AD |\n| **Lynch** | MLH1, MSH2, MSH6, PMS2 | Colorectal, endometrial | Microsatellite instability | AD |\n| **FAP** | APC | Colorectal | >100 adenomatous polyps | AD |\n| **Li-Fraumeni** | TP53 | Sarcoma, breast, brain, adrenal | Childhood cancers | AD |\n| **Cowden** | PTEN | Breast, thyroid, endometrial | Macrocephaly, hamartomas | AD |\n| **NF1** | NF1 | Neurofibromas, MPNST | Caf√©-au-lait spots, neurofibromas | AD |\n| **NF2** | NF2 | Schwannomas, meningiomas | Bilateral acoustic neuromas | AD |\n| **TSC** | TSC1, TSC2 | Renal angiomyolipomas | Seizures, mental retardation | AD |\n\n---",
      "importance": 1
    },
    {
      "id": "learning-objectives",
      "title": "Learning Objectives",
      "content": "By the end of this topic, you should be able to:\n\n1. **Distinguish** between tumor suppressor genes and oncogenes in cancer development\n2. **Apply** the two-hit hypothesis to hereditary cancer syndromes\n3. **Identify** clinical criteria for major hereditary cancer syndromes (BRCA, Lynch, FAP)\n4. **Compare** cancer risks and surveillance recommendations for different syndromes\n5. **Explain** genotype-phenotype correlations in cancer genetics\n6. **Recognize** phenotypic features of phakomatoses (NF1, NF2, TSC)\n7. **Describe** genetic testing strategies and management protocols\n8. **Analyze** family history patterns suggestive of hereditary cancer\n\n---",
      "importance": 1
    },
    {
      "id": "cancer-genetics-fundamentals",
      "title": "Cancer Genetics Fundamentals",
      "content": "<details>\n<summary><strong>üî¨ Key Concepts</strong> (Click to expand)</summary>\n\n**Two-Hit Hypothesis (Knudson):**\n- **First hit**: Germline mutation (inherited)\n- **Second hit**: Somatic mutation (acquired)\n- Result: Loss of both functional copies ‚Üí cancer development\n\n**Types of Cancer Genes:**\n- **Tumor Suppressor Genes**: \"Brakes\" - prevent cancer when functional\n  - Examples: TP53, RB1, APC, BRCA1/2\n- **Oncogenes**: \"Accelerator\" - promote growth when activated\n  - Examples: RET, MYC, EGFR\n\n**Inheritance Patterns:**\n- Most hereditary cancers: **Autosomal Dominant**\n- Variable penetrance and expressivity\n- Anticipation in some syndromes\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)**\n\n---",
      "importance": 1
    },
    {
      "id": "hereditary-breast-ovarian-cancer",
      "title": "HEREDITARY BREAST & OVARIAN CANCER",
      "content": "### BRCA1/BRCA2 Syndromes ‚≠ê‚≠ê‚≠ê\n**Most Important Cancer Syndrome - Study This First!**\n\n#### üîë Key Features (Top 3)\n1. **Breast cancer** - female and male (especially triple-negative for BRCA1)\n2. **Ovarian cancer** - epithelial type\n3. **Early age of onset** - often <50 years\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n**BRCA1:**\n- **Breast cancer**: 55-72% lifetime risk\n- **Ovarian cancer**: 39-44% lifetime risk\n- **Male breast cancer**: <1% lifetime risk\n- **Prostate cancer**: Moderate increase\n\n**BRCA2:**\n- **Breast cancer**: 45-69% lifetime risk  \n- **Ovarian cancer**: 11-17% lifetime risk\n- **Male breast cancer**: 6-8% lifetime risk\n- **Pancreatic cancer**: 1-3% lifetime risk\n- **Melanoma**: 2.5x increased risk\n- **Prostate cancer**: 20% lifetime risk (high-grade)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Features</strong> (Click to expand)</summary>\n\n- **BRCA1**: Chromosome 17q21, DNA repair (homologous recombination)\n- **BRCA2**: Chromosome 13q12-13, DNA repair (homologous recombination)\n- **Founder mutations** (Ashkenazi Jewish):\n  - 185delAG (BRCA1)\n  - 5382insC (BRCA1)  \n  - 6174delT (BRCA2)\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant\n- **Prevalence**: 1/400-500 general population; 1/40 Ashkenazi Jewish\n- **Penetrance**: Variable, influenced by modifying factors\n\n</details>\n\n#### üíé Board Pearls\n- BRCA1 tumors: Triple-negative, basal-like\n- BRCA2 tumors: ER+, HER2-, luminal\n- Male BRCA2 carriers have higher breast cancer risk than BRCA1\n- Consider testing if ‚â•10% chance of mutation (family history models)\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Cowden Syndrome](#cowden-syndrome-pten-)**\n\n---\n\n### Cowden Syndrome (PTEN) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Macrocephaly** - large head circumference\n2. **Trichilemmomas** - skin lesions on face\n3. **Multiple cancer risks** - breast, thyroid, endometrial\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n- **Breast cancer**: 85% lifetime risk\n- **Thyroid cancer**: 35% (follicular type)\n- **Endometrial cancer**: 28%\n- **Renal cancer**: 34%\n- **Colorectal cancer**: 9%\n\n</details>\n\n<details>\n<summary><strong>üé≠ Clinical Features</strong> (Click to expand)</summary>\n\n- **Dermatologic**: Trichilemmomas, papillomatous papules, acral keratoses\n- **GI**: Hamartomatous polyps, lipomas\n- **Neurologic**: Macrocephaly, cerebellar tumors (Lhermitte-Duclos)\n- **Other**: Goiter, autism spectrum (some cases)\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: PTEN (chromosome 10q23)\n- **Inheritance**: AD, 10-50% de novo\n- **Prevalence**: 1/200,000\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Colorectal Cancer Syndromes](#Ô∏è-hereditary-colorectal-cancer)**\n\n---",
      "importance": 1
    },
    {
      "id": "hereditary-colorectal-cancer",
      "title": "HEREDITARY COLORECTAL CANCER",
      "content": "### Lynch Syndrome (HNPCC) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Colorectal cancer** - often right-sided, early onset\n2. **Endometrial cancer** - most common extracolonic cancer\n3. **MSI-High tumors** - microsatellite instability\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n**MLH1/MSH2 (higher penetrance):**\n- **Colorectal**: 52-82% (males), 35-51% (females)\n- **Endometrial**: 25-60%\n- **Ovarian**: 4-24%\n\n**MSH6/PMS2 (lower penetrance):**\n- **Colorectal**: 10-22% (MSH6), 15-20% (PMS2)\n- **Endometrial**: 16-26% (MSH6), 15% (PMS2)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Mechanism</strong> (Click to expand)</summary>\n\n- **Genes**: MLH1, MSH2, MSH6, PMS2 (mismatch repair)\n- **Protein pairs**: MLH1/PMS2, MSH2/MSH6\n- **Tumor characteristics**: MSI-High, loss of IHC staining\n\n</details>\n\n<details>\n<summary><strong>üé≠ Associated Syndromes</strong> (Click to expand)</summary>\n\n- **Turcot syndrome**: Lynch + brain tumors (glioblastoma)\n- **Muir-Torre syndrome**: Lynch + sebaceous tumors\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant\n- **Prevalence**: 1/440 (most common hereditary CRC syndrome)\n\n</details>\n\n#### üíé Board Pearls\n- Amsterdam criteria: 3-2-1 rule (3 affected, 2 generations, 1 <50 years)\n- Bethesda criteria: More sensitive for testing\n- Universal tumor screening recommended\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Familial Adenomatous Polyposis](#familial-adenomatous-polyposis-fap-)**\n\n---\n\n### Familial Adenomatous Polyposis (FAP) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **>100 colon polyps** - typically hundreds to thousands\n2. **100% cancer risk** - if untreated\n3. **Extracolonic features** - CHRPE, desmoids, dental\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n- **Colorectal**: 100% by age 40-50 if untreated\n- **Duodenal**: 4-12% lifetime risk\n- **Thyroid**: 2% (papillary type)\n- **Hepatoblastoma**: Childhood risk\n- **Medulloblastoma**: Turcot variant\n\n</details>\n\n<details>\n<summary><strong>üé≠ Extracolonic Features</strong> (Click to expand)</summary>\n\n- **CHRPE**: Congenital hypertrophy of retinal pigment epithelium\n- **Desmoid tumors**: Aggressive fibromatosis\n- **Dental**: Supernumerary teeth, odontomas\n- **Bone**: Osteomas, jaw cysts\n- **Skin**: Epidermoid cysts\n\n</details>\n\n<details>\n<summary><strong>üìà Variants</strong> (Click to expand)</summary>\n\n- **Classic FAP**: >100 polyps, APC mutations 5' end\n- **Attenuated FAP**: 10-100 polyps, APC mutations 3' end\n- **Gardner syndrome**: FAP + extracolonic features\n- **Turcot syndrome**: FAP + medulloblastoma\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: APC (chromosome 5q21)\n- **Inheritance**: AD, 25% de novo\n- **Prevalence**: 1/7,000\n- **AJ founder mutation**: I1307K (moderate risk increase)\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Li-Fraumeni Syndrome](#li-fraumeni-syndrome-tp53-)**\n\n---",
      "importance": 1
    },
    {
      "id": "additional-cancer-syndromes",
      "title": "Additional Cancer Syndromes",
      "content": "### Li-Fraumeni Syndrome (TP53) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Core cancers**: Adrenal cortical carcinoma, Breast, Brain, Bone/soft tissue sarcomas\n2. **Early onset** - often childhood/young adult\n3. **Multiple primary cancers** - up to 90% lifetime risk\n\n<details>\n<summary><strong>üè• Cancer Spectrum</strong> (Click to expand)</summary>\n\n- **Adrenal cortical carcinoma**: Childhood hallmark\n- **Breast cancer**: Triple-positive, early onset\n- **Brain tumors**: Glioblastoma, choroid plexus carcinoma\n- **Sarcomas**: Osteosarcoma, soft tissue sarcomas\n- **Other**: Leukemia, lung, colorectal, pancreatic\n\n</details>\n\n<details>\n<summary><strong>‚ö†Ô∏è Clinical Management</strong> (Click to expand)</summary>\n\n- **Avoid radiation** - extreme radiation sensitivity\n- **Whole body MRI**: Annual screening protocol\n- **Early detection focus**: Cannot prevent, focus on early detection\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: TP53 (chromosome 17p13) - \"guardian of the genome\"\n- **Inheritance**: AD, 7-20% de novo\n- **Prevalence**: 1/4,000; founder mutation in Brazil (1/375)\n\n</details>\n\n#### üíé Board Pearls\n- Classic criteria: Proband <45y + 1st/2nd degree relative <45y + 1st/2nd degree relative with LFS tumor\n- R337H mutation: Brazilian founder, lower penetrance\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Phakomatoses](#-phakomatoses-neurocutaneous-syndromes)**\n\n---\n\n### von Hippel-Lindau Syndrome (VHL) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Renal cell carcinoma** - clear cell type\n2. **Hemangioblastomas** - brain, spinal cord, retina\n3. **Childhood onset** possible\n\n#### üè• Clinical Features\n- **CNS**: Hemangioblastomas (brain/spinal cord)\n- **Ophthalmologic**: Retinal hemangioblastomas\n- **Renal**: Clear cell RCC, renal cysts\n- **Pancreatic**: Pancreatic NETs, cysts\n- **Adrenal**: Pheochromocytoma/paraganglioma\n- **Ear**: Endolymphatic sac tumors\n\n#### üìà VHL Subtypes\n- **Type 1**: No pheochromocytoma risk\n- **Type 2A**: Pheochromocytoma + hemangioblastomas\n- **Type 2B**: All features including RCC\n- **Type 2C**: Pheochromocytoma only\n\n#### üìà Inheritance & Statistics\n- **Gene**: VHL (chromosome 3p25-26)\n- **Inheritance**: AD, 20% de novo\n- **Prevalence**: 1/36,000\n\n---",
      "importance": 1
    },
    {
      "id": "phakomatoses-neurocutaneous-syndromes",
      "title": "PHAKOMATOSES (Neurocutaneous Syndromes)",
      "content": "### Neurofibromatosis Type 1 (NF1) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Caf√© au lait macules** - ‚â•6 spots >5mm (prepubertal)\n2. **Neurofibromas** - benign nerve tumors\n3. **Learning difficulties** - 50% of patients\n\n#### üè• Clinical Features & Cancer Risks\n- **Dermatologic**: Caf√© au lait spots, axillary/inguinal freckling\n- **Neurologic**: Optic gliomas, learning disabilities, seizures\n- **Ophthalmologic**: Lisch nodules (iris hamartomas)\n- **Malignancies**: \n  - Malignant peripheral nerve sheath tumors (MPNST)\n  - Breast cancer (women)\n  - GI stromal tumors (GIST)\n  - Pheochromocytoma\n\n#### üìã Diagnostic Criteria (Need 2 of 7)\n1. **‚â•6 caf√© au lait macules** (>5mm prepubertal, >15mm postpubertal)\n2. **‚â•2 neurofibromas** OR 1 plexiform neurofibroma\n3. **Axillary or inguinal freckling**\n4. **Optic glioma**\n5. **‚â•2 Lisch nodules**\n6. **Distinctive bony lesion** (sphenoid dysplasia, tibial pseudarthrosis)\n7. **First-degree relative with NF1**\n\n#### üìà Inheritance & Statistics\n- **Gene**: NF1 (chromosome 17q11.2)\n- **Inheritance**: AD, 50% de novo\n- **Prevalence**: 1/3,000\n\n---\n\n### Neurofibromatosis Type 2 (NF2) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Bilateral vestibular schwannomas** - pathognomonic\n2. **Hearing loss** - progressive, sensorineural\n3. **Meningiomas** - often multiple\n\n#### üè• Clinical Features\n- **Neurologic**: Schwannomas (vestibular, cranial, spinal), meningiomas\n- **Ophthalmologic**: Cataracts (cortical wedge), retinal hamartomas\n- **Dermatologic**: Skin plaques, caf√© au lait spots (fewer than NF1)\n- **Other**: Ependymomas, facial nerve weakness\n\n#### ‚ö†Ô∏è Management Considerations\n- **Avoid radiation** - increased tumor risk\n- **Hearing preservation** - key quality of life issue\n- **Surgical planning** - multidisciplinary approach\n\n#### üìà Inheritance & Statistics\n- **Gene**: NF2 (chromosome 22q12)\n- **Inheritance**: AD, 50% de novo  \n- **Prevalence**: 1/60,000\n\n---\n\n### Tuberous Sclerosis Complex (TSC) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Facial angiofibromas** - \"adenoma sebaceum\"\n2. **Cortical tubers** - brain lesions causing seizures\n3. **Hamartomas** - multiple organ systems\n\n#### üè• Clinical Features\n- **Neurologic**: Cortical tubers, SEGAs, seizures, autism\n- **Dermatologic**: Facial angiofibromas, ash leaf spots, shagreen patches\n- **Renal**: Angiomyolipomas, renal cell carcinoma\n- **Cardiac**: Rhabdomyomas (often regress)\n- **Pulmonary**: Lymphangioleiomyomatosis (LAM) in women\n\n#### üìà TSC1 vs TSC2\n- **TSC1** (hamartin): Milder phenotype\n- **TSC2** (tuberin): More severe, more common\n\n#### üìà Inheritance & Statistics\n- **Genes**: TSC1 (9q34), TSC2 (16p13)\n- **Inheritance**: AD, 2/3 de novo\n- **Prevalence**: 1/6,000\n\n---",
      "importance": 1
    },
    {
      "id": "endocrine-neoplasia-syndromes",
      "title": "\udd2c ENDOCRINE NEOPLASIA SYNDROMES",
      "content": "### Multiple Endocrine Neoplasia Type 1 (MEN1) ‚≠ê‚≠ê\n\n#### üîë Key Features - \"PPP\"\n1. **Pituitary adenomas** - prolactinomas most common\n2. **Primary hyperparathyroidism** - earliest/most common\n3. **Pancreatic neuroendocrine tumors** - gastrinomas, insulinomas\n\n#### üè• Clinical Features\n- **Parathyroid**: Hyperparathyroidism (>95% by age 50)\n- **Pituitary**: Adenomas (prolactin, growth hormone)\n- **Pancreatic**: NETs (gastrinomas ‚Üí Zollinger-Ellison)\n- **Other**: Adrenal adenomas, carcinoid tumors, lipomas\n\n#### üìà Inheritance & Statistics\n- **Gene**: MEN1 (chromosome 11q13)\n- **Inheritance**: AD, 10% de novo\n- **Prevalence**: 1/30,000\n\n#### üíé Board Pearls\n- Hyperparathyroidism usually first manifestation\n- Foregut NETs have highest malignant potential\n- Screen family members starting age 5\n\n---\n\n### Multiple Endocrine Neoplasia Type 2 (MEN2) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Medullary thyroid carcinoma** - C-cell derived\n2. **Pheochromocytoma** - bilateral, benign usually\n3. **Early age of onset** - can be childhood\n\n#### üè• Clinical Subtypes\n\n**MEN2A (95%):**\n- Medullary thyroid carcinoma\n- Pheochromocytoma\n- Primary hyperparathyroidism\n\n**MEN2B (5%):**\n- Medullary thyroid carcinoma (aggressive)\n- Pheochromocytoma  \n- Mucosal neuromas\n- Marfanoid habitus\n- Hirschsprung disease\n\n#### üß¨ Genotype-Phenotype Correlations\n- **MEN2A**: Cysteine mutations (codons 630, 634)\n- **MEN2B**: M918T mutation (codon 918) in 95%\n- **Risk stratification**: Guides timing of prophylactic thyroidectomy\n\n#### üìà Inheritance & Statistics\n- **Gene**: RET proto-oncogene (chromosome 10q11.2)\n- **Inheritance**: AD\n  - MEN2A: 5% de novo\n  - MEN2B: 50% de novo\n- **Prevalence**: 1/35,000\n\n---",
      "importance": 1
    },
    {
      "id": "pediatric-cancer-syndrome",
      "title": "\udc41 PEDIATRIC CANCER SYNDROME",
      "content": "### Retinoblastoma (RB1) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Retinoblastoma** - eye tumor, can be bilateral\n2. **Early onset** - presents before age 5\n3. **Secondary cancers** - osteosarcoma, soft tissue sarcomas\n\n#### üè• Clinical Features\n- **Ocular**: Retinoblastoma (bilateral in germline cases)\n- **Secondary cancers**: Osteosarcoma, soft tissue sarcomas, melanoma\n- **Presentation**: Leukocoria (white pupil), strabismus\n\n#### üìä Germline vs Somatic\n- **Bilateral cases**: ~100% germline RB1 mutations\n- **Unilateral cases**: ~8% germline RB1 mutations\n- **All retinoblastoma**: 30-40% have germline mutations\n\n#### üìà Inheritance & Statistics\n- **Gene**: RB1 (chromosome 13q14)\n- **Inheritance**: AD, 90% de novo\n- **Prevalence**: 1/15,000\n\n#### üíé Board Pearls\n- First tumor suppressor gene discovered (Knudson)\n- Bilateral = germline until proven otherwise\n- High risk secondary cancers in radiation field\n\n---",
      "importance": 1
    },
    {
      "id": "study-tips-mnemonics",
      "title": "Study Tips & Mnemonics",
      "content": "<details>\n<summary><strong>üî¢ Cancer Gene Memory Aids</strong> (Click to expand)</summary>\n\n**BRCA Differences**:\n- **\"BRCA1 = 1st to get cancer\"** - Higher breast/ovarian risks\n- **\"BRCA2 = 2nd hits more organs\"** - Pancreas, prostate, melanoma\n\n**Lynch Syndrome**:\n- **\"HEMP\"** - Heart (endometrial), **E**ndometrial, **M**MSH genes, **P**olyps (fewer)\n- **\"Lynch = Links colon to uterus\"**\n\n**FAP Memory**:\n- **\"Thousands of polyps, Certain cancer\"**\n- **\"CHRPE = Can't Hide Retinal Pigment Easily\"**\n\n**Li-Fraumeni**:\n- **\"ABBS\"** - **A**drenal, **B**reast, **B**rain, **S**arcoma\n- **\"TP53 = The Guardian fails = Total Problems\"**\n\n**MEN Syndromes**:\n- **MEN1 = \"PPP\"** - Pituitary, Parathyroid, Pancreatic\n- **MEN2 = \"MTC + Pheos\"** - Medullary Thyroid Cancer + Pheochromocytoma\n\n</details>\n\n<details>\n<summary><strong>üìä Penetrance Memory Aid</strong> (Click to expand)</summary>\n\n**\"High vs Lower Penetrance\"**:\n- **High**: BRCA1/2, TP53, APC, MLH1/MSH2\n- **Lower**: MSH6/PMS2, CHEK2, ATM\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: High-Yield Facts](#-high-yield-facts-summary)**\n\n---",
      "importance": 1
    }
  ],
  "objectives": [],
  "sectionCount": 14,
  "rawContent": "# Topic 2: Cancer Genetics - Hereditary Cancer Syndromes\n\n## üìñ Quick Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Chromosomal Disorders](topic1-chromosomal-disorders.md)** | **[‚û°Ô∏è Next: Organ Systems](topic3-organ-systems-a.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üß¨ Cancer Genetics Fundamentals](#-cancer-genetics-fundamentals)\n- [üéÄ Hereditary Breast & Ovarian Cancer](#-hereditary-breast--ovarian-cancer)\n  - [BRCA1/BRCA2 Syndromes ‚≠ê‚≠ê‚≠ê](#brca1brca2-syndromes-)\n  - [Cowden Syndrome (PTEN) ‚≠ê‚≠ê](#cowden-syndrome-pten-)\n  - [Li-Fraumeni Syndrome ‚≠ê‚≠ê](#li-fraumeni-syndrome-tp53-)\n- [üéóÔ∏è Hereditary Colorectal Cancer](#Ô∏è-hereditary-colorectal-cancer)\n  - [Lynch Syndrome ‚≠ê‚≠ê‚≠ê](#lynch-syndrome-)\n  - [Familial Adenomatous Polyposis ‚≠ê‚≠ê‚≠ê](#familial-adenomatous-polyposis-fap-)\n  - [MUTYH-Associated Polyposis ‚≠ê‚≠ê](#mutyh-associated-polyposis-map-)\n- [üß† Phakomatoses (Neurocutaneous Syndromes)](#-phakomatoses-neurocutaneous-syndromes)\n  - [Neurofibromatosis Type 1 ‚≠ê‚≠ê‚≠ê](#neurofibromatosis-type-1-nf1-)\n  - [Neurofibromatosis Type 2 ‚≠ê‚≠ê](#neurofibromatosis-type-2-nf2-)\n  - [Tuberous Sclerosis Complex ‚≠ê‚≠ê](#tuberous-sclerosis-complex-tsc-)\n- [ü´Ä Additional Cancer Syndromes](#-additional-cancer-syndromes)\n- [üß† Study Tips & Mnemonics](#-study-tips--mnemonics)\n- [üìù High-Yield Facts Summary](#-high-yield-facts-summary)\n- [üéØ Practice Questions](#-practice-questions)\n- [üèÅ Topic 2 Completion Checklist](#-topic-2-completion-checklist)\n\n### üîç Quick Syndrome Lookup\n| Syndrome | Gene(s) | Primary Cancers | Key Features | Inheritance |\n|----------|---------|-----------------|--------------|-------------|\n| **BRCA1/2** | BRCA1, BRCA2 | Breast, ovarian | Early onset, family history | AD |\n| **Lynch** | MLH1, MSH2, MSH6, PMS2 | Colorectal, endometrial | Microsatellite instability | AD |\n| **FAP** | APC | Colorectal | >100 adenomatous polyps | AD |\n| **Li-Fraumeni** | TP53 | Sarcoma, breast, brain, adrenal | Childhood cancers | AD |\n| **Cowden** | PTEN | Breast, thyroid, endometrial | Macrocephaly, hamartomas | AD |\n| **NF1** | NF1 | Neurofibromas, MPNST | Caf√©-au-lait spots, neurofibromas | AD |\n| **NF2** | NF2 | Schwannomas, meningiomas | Bilateral acoustic neuromas | AD |\n| **TSC** | TSC1, TSC2 | Renal angiomyolipomas | Seizures, mental retardation | AD |\n\n---\n\n## üéØ Learning Objectives\n\nBy the end of this topic, you should be able to:\n\n1. **Distinguish** between tumor suppressor genes and oncogenes in cancer development\n2. **Apply** the two-hit hypothesis to hereditary cancer syndromes\n3. **Identify** clinical criteria for major hereditary cancer syndromes (BRCA, Lynch, FAP)\n4. **Compare** cancer risks and surveillance recommendations for different syndromes\n5. **Explain** genotype-phenotype correlations in cancer genetics\n6. **Recognize** phenotypic features of phakomatoses (NF1, NF2, TSC)\n7. **Describe** genetic testing strategies and management protocols\n8. **Analyze** family history patterns suggestive of hereditary cancer\n\n---\n\n## üß¨ Cancer Genetics Fundamentals\n\n<details>\n<summary><strong>üî¨ Key Concepts</strong> (Click to expand)</summary>\n\n**Two-Hit Hypothesis (Knudson):**\n- **First hit**: Germline mutation (inherited)\n- **Second hit**: Somatic mutation (acquired)\n- Result: Loss of both functional copies ‚Üí cancer development\n\n**Types of Cancer Genes:**\n- **Tumor Suppressor Genes**: \"Brakes\" - prevent cancer when functional\n  - Examples: TP53, RB1, APC, BRCA1/2\n- **Oncogenes**: \"Accelerator\" - promote growth when activated\n  - Examples: RET, MYC, EGFR\n\n**Inheritance Patterns:**\n- Most hereditary cancers: **Autosomal Dominant**\n- Variable penetrance and expressivity\n- Anticipation in some syndromes\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)**\n\n---\n\n## üéÄ HEREDITARY BREAST & OVARIAN CANCER\n\n### BRCA1/BRCA2 Syndromes ‚≠ê‚≠ê‚≠ê\n**Most Important Cancer Syndrome - Study This First!**\n\n#### üîë Key Features (Top 3)\n1. **Breast cancer** - female and male (especially triple-negative for BRCA1)\n2. **Ovarian cancer** - epithelial type\n3. **Early age of onset** - often <50 years\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n**BRCA1:**\n- **Breast cancer**: 55-72% lifetime risk\n- **Ovarian cancer**: 39-44% lifetime risk\n- **Male breast cancer**: <1% lifetime risk\n- **Prostate cancer**: Moderate increase\n\n**BRCA2:**\n- **Breast cancer**: 45-69% lifetime risk  \n- **Ovarian cancer**: 11-17% lifetime risk\n- **Male breast cancer**: 6-8% lifetime risk\n- **Pancreatic cancer**: 1-3% lifetime risk\n- **Melanoma**: 2.5x increased risk\n- **Prostate cancer**: 20% lifetime risk (high-grade)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Features</strong> (Click to expand)</summary>\n\n- **BRCA1**: Chromosome 17q21, DNA repair (homologous recombination)\n- **BRCA2**: Chromosome 13q12-13, DNA repair (homologous recombination)\n- **Founder mutations** (Ashkenazi Jewish):\n  - 185delAG (BRCA1)\n  - 5382insC (BRCA1)  \n  - 6174delT (BRCA2)\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant\n- **Prevalence**: 1/400-500 general population; 1/40 Ashkenazi Jewish\n- **Penetrance**: Variable, influenced by modifying factors\n\n</details>\n\n#### üíé Board Pearls\n- BRCA1 tumors: Triple-negative, basal-like\n- BRCA2 tumors: ER+, HER2-, luminal\n- Male BRCA2 carriers have higher breast cancer risk than BRCA1\n- Consider testing if ‚â•10% chance of mutation (family history models)\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Cowden Syndrome](#cowden-syndrome-pten-)**\n\n---\n\n### Cowden Syndrome (PTEN) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Macrocephaly** - large head circumference\n2. **Trichilemmomas** - skin lesions on face\n3. **Multiple cancer risks** - breast, thyroid, endometrial\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n- **Breast cancer**: 85% lifetime risk\n- **Thyroid cancer**: 35% (follicular type)\n- **Endometrial cancer**: 28%\n- **Renal cancer**: 34%\n- **Colorectal cancer**: 9%\n\n</details>\n\n<details>\n<summary><strong>üé≠ Clinical Features</strong> (Click to expand)</summary>\n\n- **Dermatologic**: Trichilemmomas, papillomatous papules, acral keratoses\n- **GI**: Hamartomatous polyps, lipomas\n- **Neurologic**: Macrocephaly, cerebellar tumors (Lhermitte-Duclos)\n- **Other**: Goiter, autism spectrum (some cases)\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: PTEN (chromosome 10q23)\n- **Inheritance**: AD, 10-50% de novo\n- **Prevalence**: 1/200,000\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Colorectal Cancer Syndromes](#Ô∏è-hereditary-colorectal-cancer)**\n\n---\n\n## üéóÔ∏è HEREDITARY COLORECTAL CANCER\n\n### Lynch Syndrome (HNPCC) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Colorectal cancer** - often right-sided, early onset\n2. **Endometrial cancer** - most common extracolonic cancer\n3. **MSI-High tumors** - microsatellite instability\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n**MLH1/MSH2 (higher penetrance):**\n- **Colorectal**: 52-82% (males), 35-51% (females)\n- **Endometrial**: 25-60%\n- **Ovarian**: 4-24%\n\n**MSH6/PMS2 (lower penetrance):**\n- **Colorectal**: 10-22% (MSH6), 15-20% (PMS2)\n- **Endometrial**: 16-26% (MSH6), 15% (PMS2)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Mechanism</strong> (Click to expand)</summary>\n\n- **Genes**: MLH1, MSH2, MSH6, PMS2 (mismatch repair)\n- **Protein pairs**: MLH1/PMS2, MSH2/MSH6\n- **Tumor characteristics**: MSI-High, loss of IHC staining\n\n</details>\n\n<details>\n<summary><strong>üé≠ Associated Syndromes</strong> (Click to expand)</summary>\n\n- **Turcot syndrome**: Lynch + brain tumors (glioblastoma)\n- **Muir-Torre syndrome**: Lynch + sebaceous tumors\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant\n- **Prevalence**: 1/440 (most common hereditary CRC syndrome)\n\n</details>\n\n#### üíé Board Pearls\n- Amsterdam criteria: 3-2-1 rule (3 affected, 2 generations, 1 <50 years)\n- Bethesda criteria: More sensitive for testing\n- Universal tumor screening recommended\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Familial Adenomatous Polyposis](#familial-adenomatous-polyposis-fap-)**\n\n---\n\n### Familial Adenomatous Polyposis (FAP) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **>100 colon polyps** - typically hundreds to thousands\n2. **100% cancer risk** - if untreated\n3. **Extracolonic features** - CHRPE, desmoids, dental\n\n<details>\n<summary><strong>üè• Cancer Risks</strong> (Click to expand)</summary>\n\n- **Colorectal**: 100% by age 40-50 if untreated\n- **Duodenal**: 4-12% lifetime risk\n- **Thyroid**: 2% (papillary type)\n- **Hepatoblastoma**: Childhood risk\n- **Medulloblastoma**: Turcot variant\n\n</details>\n\n<details>\n<summary><strong>üé≠ Extracolonic Features</strong> (Click to expand)</summary>\n\n- **CHRPE**: Congenital hypertrophy of retinal pigment epithelium\n- **Desmoid tumors**: Aggressive fibromatosis\n- **Dental**: Supernumerary teeth, odontomas\n- **Bone**: Osteomas, jaw cysts\n- **Skin**: Epidermoid cysts\n\n</details>\n\n<details>\n<summary><strong>üìà Variants</strong> (Click to expand)</summary>\n\n- **Classic FAP**: >100 polyps, APC mutations 5' end\n- **Attenuated FAP**: 10-100 polyps, APC mutations 3' end\n- **Gardner syndrome**: FAP + extracolonic features\n- **Turcot syndrome**: FAP + medulloblastoma\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: APC (chromosome 5q21)\n- **Inheritance**: AD, 25% de novo\n- **Prevalence**: 1/7,000\n- **AJ founder mutation**: I1307K (moderate risk increase)\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Li-Fraumeni Syndrome](#li-fraumeni-syndrome-tp53-)**\n\n---\n\n## ü´Ä Additional Cancer Syndromes\n\n### Li-Fraumeni Syndrome (TP53) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Core cancers**: Adrenal cortical carcinoma, Breast, Brain, Bone/soft tissue sarcomas\n2. **Early onset** - often childhood/young adult\n3. **Multiple primary cancers** - up to 90% lifetime risk\n\n<details>\n<summary><strong>üè• Cancer Spectrum</strong> (Click to expand)</summary>\n\n- **Adrenal cortical carcinoma**: Childhood hallmark\n- **Breast cancer**: Triple-positive, early onset\n- **Brain tumors**: Glioblastoma, choroid plexus carcinoma\n- **Sarcomas**: Osteosarcoma, soft tissue sarcomas\n- **Other**: Leukemia, lung, colorectal, pancreatic\n\n</details>\n\n<details>\n<summary><strong>‚ö†Ô∏è Clinical Management</strong> (Click to expand)</summary>\n\n- **Avoid radiation** - extreme radiation sensitivity\n- **Whole body MRI**: Annual screening protocol\n- **Early detection focus**: Cannot prevent, focus on early detection\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Gene**: TP53 (chromosome 17p13) - \"guardian of the genome\"\n- **Inheritance**: AD, 7-20% de novo\n- **Prevalence**: 1/4,000; founder mutation in Brazil (1/375)\n\n</details>\n\n#### üíé Board Pearls\n- Classic criteria: Proband <45y + 1st/2nd degree relative <45y + 1st/2nd degree relative with LFS tumor\n- R337H mutation: Brazilian founder, lower penetrance\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Phakomatoses](#-phakomatoses-neurocutaneous-syndromes)**\n\n---\n\n### von Hippel-Lindau Syndrome (VHL) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Renal cell carcinoma** - clear cell type\n2. **Hemangioblastomas** - brain, spinal cord, retina\n3. **Childhood onset** possible\n\n#### üè• Clinical Features\n- **CNS**: Hemangioblastomas (brain/spinal cord)\n- **Ophthalmologic**: Retinal hemangioblastomas\n- **Renal**: Clear cell RCC, renal cysts\n- **Pancreatic**: Pancreatic NETs, cysts\n- **Adrenal**: Pheochromocytoma/paraganglioma\n- **Ear**: Endolymphatic sac tumors\n\n#### üìà VHL Subtypes\n- **Type 1**: No pheochromocytoma risk\n- **Type 2A**: Pheochromocytoma + hemangioblastomas\n- **Type 2B**: All features including RCC\n- **Type 2C**: Pheochromocytoma only\n\n#### üìà Inheritance & Statistics\n- **Gene**: VHL (chromosome 3p25-26)\n- **Inheritance**: AD, 20% de novo\n- **Prevalence**: 1/36,000\n\n---\n\n## üß† PHAKOMATOSES (Neurocutaneous Syndromes)\n\n### Neurofibromatosis Type 1 (NF1) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Caf√© au lait macules** - ‚â•6 spots >5mm (prepubertal)\n2. **Neurofibromas** - benign nerve tumors\n3. **Learning difficulties** - 50% of patients\n\n#### üè• Clinical Features & Cancer Risks\n- **Dermatologic**: Caf√© au lait spots, axillary/inguinal freckling\n- **Neurologic**: Optic gliomas, learning disabilities, seizures\n- **Ophthalmologic**: Lisch nodules (iris hamartomas)\n- **Malignancies**: \n  - Malignant peripheral nerve sheath tumors (MPNST)\n  - Breast cancer (women)\n  - GI stromal tumors (GIST)\n  - Pheochromocytoma\n\n#### üìã Diagnostic Criteria (Need 2 of 7)\n1. **‚â•6 caf√© au lait macules** (>5mm prepubertal, >15mm postpubertal)\n2. **‚â•2 neurofibromas** OR 1 plexiform neurofibroma\n3. **Axillary or inguinal freckling**\n4. **Optic glioma**\n5. **‚â•2 Lisch nodules**\n6. **Distinctive bony lesion** (sphenoid dysplasia, tibial pseudarthrosis)\n7. **First-degree relative with NF1**\n\n#### üìà Inheritance & Statistics\n- **Gene**: NF1 (chromosome 17q11.2)\n- **Inheritance**: AD, 50% de novo\n- **Prevalence**: 1/3,000\n\n---\n\n### Neurofibromatosis Type 2 (NF2) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Bilateral vestibular schwannomas** - pathognomonic\n2. **Hearing loss** - progressive, sensorineural\n3. **Meningiomas** - often multiple\n\n#### üè• Clinical Features\n- **Neurologic**: Schwannomas (vestibular, cranial, spinal), meningiomas\n- **Ophthalmologic**: Cataracts (cortical wedge), retinal hamartomas\n- **Dermatologic**: Skin plaques, caf√© au lait spots (fewer than NF1)\n- **Other**: Ependymomas, facial nerve weakness\n\n#### ‚ö†Ô∏è Management Considerations\n- **Avoid radiation** - increased tumor risk\n- **Hearing preservation** - key quality of life issue\n- **Surgical planning** - multidisciplinary approach\n\n#### üìà Inheritance & Statistics\n- **Gene**: NF2 (chromosome 22q12)\n- **Inheritance**: AD, 50% de novo  \n- **Prevalence**: 1/60,000\n\n---\n\n### Tuberous Sclerosis Complex (TSC) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Facial angiofibromas** - \"adenoma sebaceum\"\n2. **Cortical tubers** - brain lesions causing seizures\n3. **Hamartomas** - multiple organ systems\n\n#### üè• Clinical Features\n- **Neurologic**: Cortical tubers, SEGAs, seizures, autism\n- **Dermatologic**: Facial angiofibromas, ash leaf spots, shagreen patches\n- **Renal**: Angiomyolipomas, renal cell carcinoma\n- **Cardiac**: Rhabdomyomas (often regress)\n- **Pulmonary**: Lymphangioleiomyomatosis (LAM) in women\n\n#### üìà TSC1 vs TSC2\n- **TSC1** (hamartin): Milder phenotype\n- **TSC2** (tuberin): More severe, more common\n\n#### üìà Inheritance & Statistics\n- **Genes**: TSC1 (9q34), TSC2 (16p13)\n- **Inheritance**: AD, 2/3 de novo\n- **Prevalence**: 1/6,000\n\n---\n\n## üî¨ ENDOCRINE NEOPLASIA SYNDROMES\n\n### Multiple Endocrine Neoplasia Type 1 (MEN1) ‚≠ê‚≠ê\n\n#### üîë Key Features - \"PPP\"\n1. **Pituitary adenomas** - prolactinomas most common\n2. **Primary hyperparathyroidism** - earliest/most common\n3. **Pancreatic neuroendocrine tumors** - gastrinomas, insulinomas\n\n#### üè• Clinical Features\n- **Parathyroid**: Hyperparathyroidism (>95% by age 50)\n- **Pituitary**: Adenomas (prolactin, growth hormone)\n- **Pancreatic**: NETs (gastrinomas ‚Üí Zollinger-Ellison)\n- **Other**: Adrenal adenomas, carcinoid tumors, lipomas\n\n#### üìà Inheritance & Statistics\n- **Gene**: MEN1 (chromosome 11q13)\n- **Inheritance**: AD, 10% de novo\n- **Prevalence**: 1/30,000\n\n#### üíé Board Pearls\n- Hyperparathyroidism usually first manifestation\n- Foregut NETs have highest malignant potential\n- Screen family members starting age 5\n\n---\n\n### Multiple Endocrine Neoplasia Type 2 (MEN2) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Medullary thyroid carcinoma** - C-cell derived\n2. **Pheochromocytoma** - bilateral, benign usually\n3. **Early age of onset** - can be childhood\n\n#### üè• Clinical Subtypes\n\n**MEN2A (95%):**\n- Medullary thyroid carcinoma\n- Pheochromocytoma\n- Primary hyperparathyroidism\n\n**MEN2B (5%):**\n- Medullary thyroid carcinoma (aggressive)\n- Pheochromocytoma  \n- Mucosal neuromas\n- Marfanoid habitus\n- Hirschsprung disease\n\n#### üß¨ Genotype-Phenotype Correlations\n- **MEN2A**: Cysteine mutations (codons 630, 634)\n- **MEN2B**: M918T mutation (codon 918) in 95%\n- **Risk stratification**: Guides timing of prophylactic thyroidectomy\n\n#### üìà Inheritance & Statistics\n- **Gene**: RET proto-oncogene (chromosome 10q11.2)\n- **Inheritance**: AD\n  - MEN2A: 5% de novo\n  - MEN2B: 50% de novo\n- **Prevalence**: 1/35,000\n\n---\n\n## üëÅÔ∏è PEDIATRIC CANCER SYNDROME\n\n### Retinoblastoma (RB1) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Retinoblastoma** - eye tumor, can be bilateral\n2. **Early onset** - presents before age 5\n3. **Secondary cancers** - osteosarcoma, soft tissue sarcomas\n\n#### üè• Clinical Features\n- **Ocular**: Retinoblastoma (bilateral in germline cases)\n- **Secondary cancers**: Osteosarcoma, soft tissue sarcomas, melanoma\n- **Presentation**: Leukocoria (white pupil), strabismus\n\n#### üìä Germline vs Somatic\n- **Bilateral cases**: ~100% germline RB1 mutations\n- **Unilateral cases**: ~8% germline RB1 mutations\n- **All retinoblastoma**: 30-40% have germline mutations\n\n#### üìà Inheritance & Statistics\n- **Gene**: RB1 (chromosome 13q14)\n- **Inheritance**: AD, 90% de novo\n- **Prevalence**: 1/15,000\n\n#### üíé Board Pearls\n- First tumor suppressor gene discovered (Knudson)\n- Bilateral = germline until proven otherwise\n- High risk secondary cancers in radiation field\n\n---\n\n## üß† Study Tips & Mnemonics\n\n<details>\n<summary><strong>üî¢ Cancer Gene Memory Aids</strong> (Click to expand)</summary>\n\n**BRCA Differences**:\n- **\"BRCA1 = 1st to get cancer\"** - Higher breast/ovarian risks\n- **\"BRCA2 = 2nd hits more organs\"** - Pancreas, prostate, melanoma\n\n**Lynch Syndrome**:\n- **\"HEMP\"** - Heart (endometrial), **E**ndometrial, **M**MSH genes, **P**olyps (fewer)\n- **\"Lynch = Links colon to uterus\"**\n\n**FAP Memory**:\n- **\"Thousands of polyps, Certain cancer\"**\n- **\"CHRPE = Can't Hide Retinal Pigment Easily\"**\n\n**Li-Fraumeni**:\n- **\"ABBS\"** - **A**drenal, **B**reast, **B**rain, **S**arcoma\n- **\"TP53 = The Guardian fails = Total Problems\"**\n\n**MEN Syndromes**:\n- **MEN1 = \"PPP\"** - Pituitary, Parathyroid, Pancreatic\n- **MEN2 = \"MTC + Pheos\"** - Medullary Thyroid Cancer + Pheochromocytoma\n\n</details>\n\n<details>\n<summary><strong>üìä Penetrance Memory Aid</strong> (Click to expand)</summary>\n\n**\"High vs Lower Penetrance\"**:\n- **High**: BRCA1/2, TP53, APC, MLH1/MSH2\n- **Lower**: MSH6/PMS2, CHEK2, ATM\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: High-Yield Facts](#-high-yield-facts-summary)**\n\n---\n\n## üìù High-Yield Facts Summary\n\n<details>\n<summary><strong>üéØ Must-Know Cancer Risks</strong> (Click to expand)</summary>\n\n- **BRCA1**: 55-72% breast, 39-44% ovarian\n- **BRCA2**: 45-69% breast, 11-17% ovarian, 6-8% male breast\n- **Lynch (MLH1/MSH2)**: 52-82% colorectal, 25-60% endometrial\n- **FAP**: 100% colorectal if untreated\n- **Li-Fraumeni**: Up to 90% any cancer\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Criteria</strong> (Click to expand)</summary>\n\n- **BRCA**: ‚â•10% mutation probability (family history models)\n- **Lynch**: Amsterdam/Bethesda criteria, universal tumor screening\n- **NF1**: Clinical criteria (need 2 of 7)\n- **Surveillance**: Gene-specific protocols, start early\n\n</details>\n\n<details>\n<summary><strong>üõ°Ô∏è Key Management Points</strong> (Click to expand)</summary>\n\n- **Li-Fraumeni**: Avoid radiation, whole body MRI\n- **VHL**: Ophthalmologic screening for retinal hemangioblastomas\n- **MEN2**: Prophylactic thyroidectomy based on mutation\n- **FAP**: Prophylactic colectomy, upper endoscopy\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Practice Questions](#-practice-questions)**\n\n---\n\n## üéØ Practice Questions\n\n> **üìù Study Tip**: Try answering these questions before clicking for the answer. These mirror actual board exam question styles.\n\n### Question 1\nA 35-year-old woman with breast cancer has a family history of ovarian cancer in her mother and pancreatic cancer in her maternal grandfather. Genetic testing is most likely to reveal a mutation in which gene?\n\n**A)** BRCA1  \n**B)** BRCA2  \n**C)** TP53  \n**D)** PALB2\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B) BRCA2**\n\nThe combination of breast cancer, ovarian cancer, and pancreatic cancer in the same family lineage is most suggestive of BRCA2. While BRCA1 is associated with breast and ovarian cancer, BRCA2 has a stronger association with pancreatic cancer (1-3% lifetime risk) and male breast cancer.\n</details>\n\n### Question 2\nA 25-year-old man presents with bilateral vestibular schwannomas and cataracts. His father had similar symptoms. What is the most likely diagnosis?\n\n**A)** Neurofibromatosis type 1  \n**B)** Neurofibromatosis type 2  \n**C)** Tuberous sclerosis complex  \n**D)** von Hippel-Lindau syndrome\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B) Neurofibromatosis type 2**\n\nBilateral vestibular schwannomas are pathognomonic for NF2. The presence of cataracts (cortical wedge type) further supports this diagnosis. NF1 rarely causes bilateral vestibular schwannomas.\n</details>\n\n### Question 3\nA family meets Amsterdam criteria for Lynch syndrome. Tumor testing on the proband's colon cancer shows MSI-high and loss of MLH1 by immunohistochemistry. What is the next most appropriate step?\n\n**A)** MLH1 germline sequencing  \n**B)** BRAF V600E testing on tumor  \n**C)** MLH1 promoter hypermethylation testing  \n**D)** Germline testing of all Lynch genes\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C) MLH1 promoter hypermethylation testing**\n\nWhen a tumor shows loss of MLH1 by IHC, the next step is to determine if this is due to somatic hypermethylation (sporadic) or germline mutation (Lynch syndrome). MLH1 promoter hypermethylation testing should be performed first. If negative, then germline testing is indicated.\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Completion Checklist](#-topic-2-completion-checklist)**\n\n---\n\n## üèÅ Topic 2 Completion Checklist\n\n### ‚úÖ Knowledge Mastery\n- [ ] Understand two-hit hypothesis and tumor suppressor vs oncogene concepts\n- [ ] Know cancer risks and features for BRCA1 vs BRCA2\n- [ ] Can distinguish Lynch syndrome from FAP\n- [ ] Understand Li-Fraumeni management (avoid radiation)\n- [ ] Recognize NF1 diagnostic criteria and NF2 key features\n- [ ] Know MEN1 vs MEN2 differences and RET genotype-phenotype\n- [ ] Understand retinoblastoma bilateral vs unilateral implications\n\n### üéØ Practice & Review\n- [ ] Completed all practice questions successfully\n- [ ] Reviewed mnemonics and memory aids\n- [ ] Can recall cancer risk percentages for major syndromes\n- [ ] Understand testing criteria and management protocols\n\n### üîÑ Self-Assessment\n- [ ] Confident distinguishing between hereditary cancer syndromes\n- [ ] Can apply testing criteria in clinical scenarios\n- [ ] Ready to move to next topic\n\n---\n\n## üîó Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Chromosomal Disorders](topic1-chromosomal-disorders.md)** | **[‚û°Ô∏è Next Topic: Organ Systems](topic3-organ-systems-a.md)**\n\n---\n\n**üïí Study Time Recommendation:** 8-10 hours  \n**üóìÔ∏è Review Schedule:** Review this topic after completing Topic 4\n\n**üèÜ Completion Status:** Topic 2 of 6 complete"
}